11:44 AM EST - Transition Therapeutics Inc. : said it has acquired the rights to a series of preclinical compounds from Eli Lilly and Co. in the area of diabetes. Under the licensing and collaboration agreement, Transition will receive exclusive worldwide rights to develop and potentially commercialize a class of compounds that, in preclinical diabetes models showed potential to provide glycemic control and other beneficial effects including weight loss. Transition Therapeutics Inc.
shares T.TTH are trading up $0.07 at $2.77.
